Skip to Content

Akero Therapeutics Inc

Rating as of

Company Profile

Business Description

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate AKR-001 is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

170 Harbor Way, 3rd Floor
South San Francisco, CA, 94080
T +1 650 487-6488
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 14